Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma

European Journal of Cancer

Volumn 38, Issue 1, 2002, Pages 83-91

  Zuzak, T J ^a   Steinhoff, D F ^a   Sutton, L N ^b   Phillips, P C ^b   Eggert, A ^c   Grotzer, M A ^a,b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Apoptosis; Brain tumour; Caspase 8; Medulloblastoma; Pathogenesis; Primitive neuroectodermal tumour; TRAIL (Apo2L)

Indexed keywords

CASPASE 3; CASPASE 8; FAS ASSOCIATED DEATH DOMAIN PROTEIN; MESSENGER RNA; PROTEIN DR5; RECEPTOR PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BRAIN TISSUE; BRAIN TUMOR; CELL LINE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INFANT; MALE; MEDULLOBLASTOMA; METHYLATION; NEUROECTODERM TUMOR; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; APOPTOSIS REGULATORY PROTEINS; BRAIN NEOPLASMS; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; CASPASES; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEDULLOBLASTOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; NEUROECTODERMAL TUMORS, PRIMITIVE; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036139396     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00355-0     Document Type: Article

References (49)

1. CNS and miscellaneous intracranial and intraspinal neoplasms
2. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study
3. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors
4. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma
5. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
6. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
7. The receptor for the cytotoxic ligand TRAIL
8. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
9. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
10. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling
11. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
12. TRAIL receptor-2 signals apoptosis through FADD and caspase-8
13. Inhibition of death receptor signals by cellular FLIP
14. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
15. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics
16. Safety and antitumor activity of recombinant soluble Apo2 ligand
17. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
18. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
19. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)
20. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression
21. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma
22. Methylation-specific PCR: A novel PCR assay for methylation status of CpG island
23. Expression of TRAIL and its receptors in human brain tumors
24. Cancer epigenetics comes of age
25. Alterations in DNA methylation: A fundamental aspect of neoplasia
26. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis
27. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
28. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
29. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
30. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression
31. Molecular determinants of response to TRAIL in killing of normal and cancer cells
32. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
33. Caspases: Enemies within
34. Apoptosis by death factor
35. The TRAIL DISCussion: It is FADD and caspase-8
36. Structure and chromosome localization of the human CASP8 gene
37. Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors
38. De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines
39. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines
40. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon
41. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns
42. A genomic scanning method for higher organisms using restriction sites as landmarks
43. A matter of life and cell death
44. Caspase 8: The killer you can't live without
45. 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present and future trends
46. Cytogenic response to low-dose 5′-aza-2′-deoxyctidine (DAC) in poor-risk myelodysplastic syndromes (MDS)
47. Mutagenicity of 5-aza-2′deoxycytidine is mediated by the mammalian DNA methyltransferase
48. Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide
49. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis